Citigroup Lowers Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $42.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its target price decreased by equities researchers at Citigroup from $45.00 to $42.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target would suggest a potential upside of 190.06% from the stock’s current price.

A number of other brokerages have also weighed in on SNDX. The Goldman Sachs Group boosted their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Scotiabank reduced their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. JPMorgan Chase & Co. raised their price objective on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday. Finally, StockNews.com cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Syndax Pharmaceuticals Trading Up 0.7 %

SNDX opened at $14.48 on Tuesday. The company has a market cap of $1.24 billion, a P/E ratio of -3.99 and a beta of 0.90. The company’s 50 day moving average is $14.29 and its 200-day moving average is $16.69. Syndax Pharmaceuticals has a 1-year low of $12.06 and a 1-year high of $25.16.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to analysts’ expectations of $86.32 million. On average, equities analysts forecast that Syndax Pharmaceuticals will post -3.72 EPS for the current year.

Insider Transactions at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 13,288 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now directly owns 300,121 shares of the company’s stock, valued at $4,651,875.50. The trade was a 4.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Keith A. Goldan sold 3,777 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the transaction, the chief financial officer now directly owns 90,746 shares in the company, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,683 shares of company stock worth $336,087 over the last three months. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SNDX. R Squared Ltd acquired a new position in shares of Syndax Pharmaceuticals during the fourth quarter valued at about $26,000. Quantbot Technologies LP acquired a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at about $49,000. Mirae Asset Global Investments Co. Ltd. increased its position in Syndax Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock worth $70,000 after buying an additional 827 shares during the period. Finally, Cape Investment Advisory Inc. raised its stake in Syndax Pharmaceuticals by 157.1% during the 4th quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock worth $85,000 after buying an additional 3,927 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).